MERSİN UNIVERSITY HOSPITAL
Slide background
Corporate

Department of Infectious Diseases


Publications in International Scientific Journals(last two years)

2020
7. Sayan, M.; özgüler, M.; Sarıgül yıldırım, F.; Yıldırmak, T.; Gündüz, A.; Dokuzoğuz, B.; çelen, M.; Inan, D.; Heper, Y. Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections. GALENOS YAYINEVI, 2020, 37, 125-130.
http://dx.doi.org/10.4274/balkanmedj.galenos.2020.2019.5.89
6. Aygen, B.; Demirturk, N.; Yildiz, O.; Celen, M.; Celik, I.; Barut, S.; Ural, O.; Batirel, A. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. AVES PUBLISHING CO., 2020, 31, 305-317.
http://dx.doi.org/10.5152/TJG.2020.19197
5. Sayan, M.; Yıldırım, F.; Akhan, S.; Yıldırım, A.; şirin, G.; Cabalak, M.; Demir, M.; Can, S.; Ersöz, G. NS5A resistance – associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. ELSEVIER BV, 2020, 95, 84-89.
http://dx.doi.org/10.1016/J.IJID.2020.03.061
2019
4. Ersöz, G. . ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2019, 18, 1-9.
doi.org/10.1186/s12941-019-0319-8
3. Ersöz, G. . EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY INFECTIOUS DISEASES, 2019, 38, 1753-1763.
10.1007/s10096-019-03607-x
2. Ersöz, G. . CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2019, 27, 223-228.
10.21101/cejph.a5467
1. Erdem, H.; Cag, Y.; Gencer, S.; Uysal, S.; Karakurt, Z.; Harman, R.; Aslan, E.; Mutlu-yilmaz, E.; Karabay, O. Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study. SPRINGER SCIENCE AND BUSINESS MEDIA LLC, 2019, 39, 45-52.
http://dx.doi.org/10.1007/S10096-019-03691-Z